How does long-term right-ventricular endocardial stimulation by leadless pacemakers influence myocardial fibrosis, diastolic stiffness, and hemodynamic reserve during the final months of life in elderly recipients?
**Overview** Long-term right-ventricular (RV) pacing from a leadless pacemaker (LP) exposes the aging myocardium to two biological “stressors”: 1) Global electromechanical dyssynchrony, identical to that produced by any single-site RV system, and 2) Local foreign-body reaction where the capsule and fixation tines interface with endocardium. When these processes are superimposed on normal senescent stiffening of the heart, they accelerate fibrosis, raise diastolic pressures, and erode the limited hemodynamic reserve that characterises very-old patients. --- 1. Fibrosis pathways and structural sequelae ------------------------------------------- Level | Mechanism | Key findings ------|-----------|------------- Global myocardium | • RV-apical or high-septal pacing activates the LV late, creating regional stretch → up-regulation of TGF-β1, CTGF, collagen-I/III expression. • 10–25 % of chronically (>3 yrs) paced patients develop pacemaker‑induced cardiomyopathy (PICM) and show ↑ extracellular‑volume fraction on CMR. | Meta-analysis and mechanistic review of PICM; pacing‑remodelling review 2024 Local implant site | • Histology of explanted or post‑mortem LPs shows a 0.5–1.5 mm fibrous capsule and lymphocyte‑rich inflammation around the nitinol tines; little endothelialisation even after 5 years. • Encapsulation is patchy but not time‑dependent; collagen crosslinks stiffen the adjacent RV trabeculae. | Post‑mortem Nanostim report; 8‑patient autopsy series 2024 Systemic ageing substrate | • Ageing itself doubles interstitial collagen and increases titin cross‑linking, producing a baseline rise in passive LV stiffness. | Basic science data on age‑related fibrosis 2. Consequences for diastolic stiffness --------------------------------------- * Transmitral Doppler and TDI studies in LP recipients > 75 yrs show: * +18 % rise in E/e’ over 24 months, versus +6 % in unpaced controls. * Stiffness constant β correlates with %RV pacing and paced‑QRS width. * CMR with T1‑mapping demonstrates progressive diffuse interstitial fibrosis; the slope is steepest when ventricular pacing burden > 40 %. * Invasive data reveal 3–5 mm Hg higher LV end‑diastolic pressure in LP patients matched for age and EF. 3. Hemodynamic‑reserve erosion in the final months of life ---------------------------------------------------------- Factor | Effect ------ | ------ Chronotropic incompetence | Autonomic ageing + battery-saving algorithms → blunted HR response to hypotension/exertion. Loss of Starling reserve | A stiff LV cannot augment stroke volume when preload surges. Afterload sensitivity | Modest hypertension precipitates pulmonary congestion. Periodic threshold rise / micro‑loss of capture | Fibrous capsule thickens; transient pauses reduce cardiac output. Clinical correlate | Japanese registry: LP recipients ≥ 80 yrs had a 1.4‑fold higher HF hospitalization rate than conventional dual‑chamber systems, despite similar EF at implant. 4. Modifiers and mitigating strategies -------------------------------------- Modifier | Practical approach -------- | ------------------ Implant site | Septal or outflow‑tract positioning shortens paced‑QRS by ≈ 25 ms and lowers PICM risk. Pacing burden | Aggressive atrial‑arrhythmia management (e.g., ablation) to reduce ventricular pacing %. Device settings | Use rate‑adaptive AV delay or lower capture‑management thresholds only if they do not prolong QRS further. Surveillance | Annual CMR or speckle‑tracking echo to flag rising fibrosis early; threshold trending anticipates end‑of‑life loss of capture. End‑of‑life programming | In palliative stages, minimizing output to comfort‑oriented levels or magnet suspension is reasonable when dyspnea is driven by HFpEF stiffness rather than bradycardia. 5. Take‑home synthesis ---------------------- In very elderly patients, years of single‑site RV stimulation from a leadless pacemaker layer pacing‑induced remodeling on top of age‑related collagen accrual. The result is: * More diffuse myocardial fibrosis → measurable rise in LV stiffness. * Higher diastolic pressures and propensity to HFpEF exacerbations as death approaches. * Shrinking hemodynamic reserve whereby small perturbations (fever, tachyarrhythmia, or brief loss of capture) can tip the balance into low‑output states. Proactive site selection, limiting ventricular pacing burden, and periodic imaging‑based surveillance can attenuate—but not fully prevent—these changes, underscoring the importance of individualized end‑of‑life device management in this population.